Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

148

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

148 results for “vemurafenib”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov28/100

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

ClinicalTrials.gov study NCT01739764. IPD Sharing: NO. Countries: 25. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

ClinicalTrials.gov study NCT01765569. IPD Sharing: Not stated. Countries: 5. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

ClinicalTrials.gov study NCT06561360. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

ClinicalTrials.gov study NCT01586195. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

ClinicalTrials.gov study NCT01378975. IPD Sharing: Not stated. Countries: 10. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

ClinicalTrials.gov study NCT03430947. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

ClinicalTrials.gov study NCT01519427. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

ClinicalTrials.gov study NCT01942993. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

ClinicalTrials.gov study NCT01781026. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo24/100

Neddylation Signaling Inactivation by Tetracaine Hydrochloride Suppresses Cell Proliferation and Vemurafenib-resistance of Melanoma

GEO Series GSE273497. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2024View details →
geo24/100

LINC01198 activates Hippo signaling to stimulate IL-1β autocrine for enhancing vemurafenib resistance in melanoma by associating with TAOK1/2

GEO Series GSE289512. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2025View details →
geo24/100

FOXD1 Promotes Dedifferentiation and Vemurafenib-resistance in Melanoma by Regulating the Expression of CTGF

GEO Series GSE162973. Homo sapiens. 14 samples. Type: Expression profiling by array.

openGEO-OpenMar 2021View details →
geo24/100

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

GEO Series GSE209769. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2023View details →
geo24/100

Melanoma GEMM Tumors, untreated or vemurafenib treated [bulk RNA-seq]

GEO Series GSE205251. Mus musculus. 34 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2022View details →
geo24/100

Gene expression of the A375 melanoma cell line treated with RAF inhibitors Vemurafenib and time-course with EGF stimulation during Vemurafenib RAF inhibitor treatment alone or with the MEK inhibitor

GEO Series GSE127988. Homo sapiens. 96 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenOct 2020View details →
geo24/100

M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental

GEO Series GSE153526. Homo sapiens. 2 samples. Type: Genome variation profiling by array.

openGEO-OpenDec 2021View details →
geo24/100

Next Generation Sequencing of human BRAF melanoma cell lines treated with vemurafenib for 20 days

GEO Series GSE152699. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2020View details →
geo24/100

Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

GEO Series GSE126714. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2019View details →
geo24/100

Gene expression signature of vemurafenib resistance in WM989 and WM983B melanoma cells

GEO Series GSE97681. Homo sapiens. 122 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2017View details →
geo24/100

Profiling melanoma cell line M14 treated with vemurafenib

GEO Series GSE134838. Homo sapiens. 2 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2020View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record